Kornimate/medical-research-clean huggingface dataset:
dual-task gait performance in people with knee osteoarthritis before and after knee replacement surgery

Conditions: Osteoarthritis, Knee

Summary: knee osteoarthritis (oa) is one of the most common conditions causing disability and limitation in the elderly population, with 13% of women and 10% of men over the age of 60 suffering from symptomatic knee osteoarthritis. pain and other symptoms of oa significantly affect the quality of life, manifesting itself in pain, decreased range of motion, functional limitation and change in gait patterns. total knee replacement surgery (tkr) is the most common solution for patients with advanced cartilage erosion and is considered a successful surgery with high satisfaction rates (about 80%). the surgery becomes necessary when pain limits the daily functioning and impairs the quality of life and after the failure of conservative treatment. still, patients undergoing tkr suffer in the first period after surgery from pain, decreased balance and proprioceptive impairment. despite the improvement in pain and function, the rates of falls after surgery do not change drastically and remain high. about a third of older adults fall each year, leading to fractures, functional decline and in some cases death. walking is a complex task, and with advancing age walking becomes less automatic and requires additional attention. among adults, it is known that an increased risk of falls is associated with reduced ability to perform complex walking tasks, such as walking while talking or crossing obstacles. after tkr, most falls occur while walking due to slipping / tripping. in addition, proprioceptive impairment, pain and poor balance are associated with an increased risk of falling after tkr. the mechanism underlying these effects may be increased allocation of cognitive resources to walking. thus, this study will examine the ability of people before and after tkr to perform complex walking tasks, in order to examine the change in attention allocation to walking following surgery. it is hypothesized that after surgery, the ability to walk while performing an additional task will be lower than prior to surgery.


Eligibility criteria:
inclusion criteria: * able to walk at least for 1 minute with no assistive device * able to understand and complete simple instructions exclusion criteria: * diagnosed dementia * diseases impairing balance * diagnosed rheumatoid arthritis

Keywords: total knee replacement cognitive load gait proprioception dual task
efficacy and safety of a subcutaneous tanezumab titration dosing regimen in subjects with moderate to severe osteoarthritis of the hip or knee

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. the study also evaluates the safety of the treatment regimens.


Eligibility criteria:
inclusion criteria: * diagnosis of osteoarthritis of the knee or hip confirmed by x-ray * documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, nsaids and either tramadol or opioids * meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline * willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol * women able to have children must agree to use 2 forms of contraception during the study exclusion criteria: * body mass index (bmi) greater than 39 * history of diseases other than osteoarthritis in a shoulder, hip or knee (example, rheumatoid arthritis, gout, joint infections, osteonecrosis) * patients with x-ray showing joint conditions such as osteonecrosis (dead bone) or certain types of fractures * patients who have had significant trauma or surgery to a knee, hip or shoulder within the previous year * planned surgical procedure during the study * patients who are largely or wholly incapacitated (example bedridden or confined to a wheelchair, permitting little or no self-care) * patients who would be unwilling or unable to undergo joint replacement surgery if one eventually became necessary * patients with significant conditions other than osteoarthritis that could interfere with assessment of pain in the joints (example fibromyalgia, lupus erythematosus) * patients with significant heart, neurological or psychiatric diseases * patients who had cancer other than certain skin cancers within the past 5 years * patients with alcohol, analgesic (pain medications) or drug abuse within the past 2 years * women who are pregnant, breast-feeding or intending to become pregnant or breast-feed during the course of the study.

Keywords: osteoarthritis of the knee osteoarthritis of the hip nerve growth factor inhibitor tanezumab
effects of complementary therapies in people with mild to moderate parkinson's disease

Conditions: Parkinson Disease

Summary: the aim of this study was to compare the effects of hatha yoga versus stretching on physical outcomes, quality of life, physical activity and motor examination in persons with parkinson disease. the hypothesis of this study is that hatha yoga will improve more than stretching on physical outcomes, quality of life, physical activity and on motor examinations in persons with parkinson diseases

individuals diagnosed with parkinson 's disease, signed up at the parkinson's association in asparbi (bilbao, basque country), and meeting the inclusion criteria were included in the study. these individuals were randomly assigned (in a 1:1 ratio) through sealed opaque envelopes to either to hatha yoga group and stretching group by coin tossing sequence generation both programs consisted of one weekly session for a total of eight weeks. hatha yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). two repetitions of 15 seconds of each stretch were performed, with 15 seconds interval between repetitions. the sessions ended with diaphragmatic breathing exercises (10 minutes). demographic information form was filled out by patients including information about: age, height (cm), weight (kg). additionally, the following measures are going to be measured: * postural control is assessed with a stabilometric platform. * flexibility ( back scratch test and chair sit and reach test) * time up and go test (tug) * 5 times sit to stand test * walking speed * unified parkinson´s diseases rating scale iii (updrs-iii) * international physical activity questionnaires (ipaq) * parkinson´s disease questionnaires- 39 (pdq-39) spss version 22 program was used in the analysis of the data. mann whitney u test, wilcoxon test, student t test and two-way mixed anova were used to analyse the results.

Eligibility criteria:
inclusion criteria: * medical diagnosis of parkinson's disease * stages i to iii on the hoehn and yahr scale * ability to stand upright unaided and walk with or without technical support exclusion criteria: * participate in another directed physical exercise program during the project. * moderate or severe cognitive decline.

Keywords: yoga stretching parkinson disease
primary sclerosing cholangitis with oral vancomycin by the study of its antimicrobial and immunomodulating effects

Conditions: Primary Sclerosing Cholangitis

Summary: determine the benefit of oral vancomycin therapy for primary sclerosing cholangitis.

the purpose of this study is to evaluate changes in the fecal and salivary/urinary microbiota during vancomycin treatment of children and adults with primary sclerosing cholangitis (psc), identify features of the host microbiota that are associated with disease activity and/or response to treatment and further delineate the immunological effects of oral vancomycin treatment of psc. this study will correlate changes in microbiota with the immunological effects of oral vancomycin in children and adults with psc. the results of this proposal will lead to new and validated targets for diagnosis and treatment of psc that will have high impact in the short and long term for patients and their families. interim results were published in abarbanel et al, j clin immunol 2013 (see references).

Eligibility criteria:
inclusion criteria: * psc diagnosis: liver biopsy and/or imaging (mrcp, ercp, ct, or us * colonoscopy within 1 year or starting of study * 2 groups: 1. ibd (inflammatory bowel disease) and psc: details of extent and type of ibd 2. no ibd and psc, but positive p-anca or asca serologies indicating possible ibd. exclusion criteria: * allergy to vancomycin * psc not associated with ibd or no positive ibd antibodies (p-anca \[anti- neutrophil cytoplasmic antibody\] or asca \[anti-saccharomyces cerevisiae antibody\]) * cholangiocarcinoma * on oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or biologics (infliximab, adalimumab, certolizumab).

Keywords: inflammation of the bile ducts biliary scarring obstruction
freeze-dried live attenuated measles/rubella combined vaccine (schwarz ff-8 strain/to-336 strain) special drug use surveillance of vaccinees after the first vaccination

Conditions: Measles/Rubella

Summary: the purpose of this survey is to assess the safety freeze-dried live attenuated measles and rubella combined vaccine (schwarz ff-8 strain/to-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine "takeda") in terms of the occurrence of unknown/known adverse drug reactions and factors that may influence the safety of vaccinees after the first vaccination.

this survey was designed to assess the safety of live attenuated measles and rubella combined vaccine (schwarz ff-8 strain/to-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine "takeda") in terms of the occurrence of unknown/known adverse drug reactions and factors that may influence the safety of vaccinees after the first vaccination. freeze-dried live attenuated measles and rubella combined vaccine (schwarz ff-8 strain/to-336 strain) is dissolved in 0.7 ml of accompanying reconstitution fluid (water for injection \[japanese pharmacopoeia\]), wherein a 0.5-ml portion is typically administered subcutaneously as a single dose. in addition, freeze-dried live attenuated measles and rubella combined vaccine (schwarz ff-8 strain/to-336 strain) should be used in accordance with the "regulations for vaccination" and the "guidelines for routine vaccination."

Eligibility criteria:
inclusion criteria: -vaccinees who meet both of the following conditions \[1\] and \[2\]: 1. vaccinees who have no prior history of either measles or rubella vaccination and who received freeze-dried live attenuated measles and rubella combined vaccine (schwarz ff-8 strain/to-336 strain) as the initial vaccination. 2. vaccinees whose guardians are able to participate in a questionnaire survey on the health status of vaccinees after vaccination with freeze-dried live attenuated measles and rubella combined vaccine (schwarz ff-8 strain/to-336 strain). exclusion criteria: -

Keywords: pharmacological therapy
osca - olaparib standard of care study

Conditions: Platinum-sensitive Recurrent Serous Ovarian Cancer

Summary: this study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer. the objectives are to describe in a real-world population, treatment patterns, brca mutation testing and results, overall survival, health care utilization and also to estimate rates of selected treatment- and/or disease-related side effects


Eligibility criteria:
inclusion criteria: 1. first determined to have platinum-sensitive recurrent serous ovarian cancer between january 1, 2009, and december 31, 2013 (study entry period), as defined by no evidence of disease progression for at least 6 months after completion of a first-line platinum-based chemotherapy regimen; the first date of platinum-sensitive recurrence between january 1, 2009 and december 31, 2013 will define the study index date. 2. at least 18 years of age on the index date. 3. fully documented medical history related to the patient's ovarian cancer treatment beginning with initial diagnosis of serous ovarian cancer. 4. patients can be either alive or deceased at the time of medical record abstraction. exclusion criteria: 1. ever taken an investigational product as part of an interventional clinical trial for ovarian cancer.

Keywords: women platinum sensitive recurrent serous ovarian cancer brca parp olaparib
effects of therapeutic artistic activities on the mental status of adolescents followed up with diabetes diagnosis

Conditions: Adolescent; Diabetes

Summary: this study will examine the effectiveness of therapeutic artistic activities in diabetic adolescents between the ages of 9-18. the study includes a 6-week program. the program will use art activities that can affect well-being, such as drawing a picture called a mandala. the state anxiety inventory will be used to measure the anxiety levels of adolescents, the psychological well-being scale to assess their well-being, and a process evaluation form to evaluate the program (such as satisfaction).

this study will be conducted with adolescents between the ages of 9-18 who are diagnosed with type 1 diabetes. the study includes a 6-week program. art activities that can affect well-being, such as drawing a picture called a mandala, will be used in the program. mandala drawing and painting will be done with the adolescents in the second and fourth weeks of the study. the drawings will be discussed in the third and fifth weeks. a common storytelling technique will be used according to the adolescents; feelings about drawing and painting. in the study, the state anxiety inventory will be used to measure the anxiety levels of the adolescents, the psychological well-being scale to evaluate their well-being, and the process evaluation form where they evaluate the program (such as satisfaction). in addition, the descriptive characteristics form, which consists of questions such as age and grade, will be applied in the first week of the study.

Eligibility criteria:
inclusion criteria: adolescents who agree to participate in the study and whose parents give written consent, * are between the ages of 9-18, * have been diagnosed with type 1 diabetes at least 6 months ago, * have internet access on their smartphone or computer, * have no other physiological or psychological illness, * do not use psychoactive drugs exclusion criteria: * those who use insulin pumps, * those who have experienced a significant life event in the last 6 months (such as migration, death, divorce in the family) * those who have practiced another body-mind based practice in the last 6 months (such as yoga, guided imagery, etc.) * those who do not have internet access
perioperative three-dimensional echocardiography in cardioanesthesia.

Conditions: Cardiac Disease; Vascular Diseases

Summary: the aim of this study is to investigate the significance of intraoperative echocardiography on the surgical course and association with patient outcome. of particular interest is the three-dimensional assessment of cardiac and valvular function. the patient course from surgery to the time of hospital discharge will be followed up.


Eligibility criteria:
inclusion criteria: * cardiac surgery or surgery on the vessels near the heart exclusion criteria: * pregnant patients * unfeasibility of intraoperative echocardiography in contraindications to transesophageal echocardiography: esophageal carcinoma, varices, diverticula, strictures, acute esophagitis, previous esophageal or gastric bleeding, symptomatic hiatal hernia. * no written consent obtainable.
study for appropriate operating table height for endotracheal intubation under direct laryngoscopy

Conditions: Larynx

Summary: laryngeal view of the patient and anesthesiologist's discomfort level during endotracheal intubation in relation to the various heights of operating table has not been investigated. the investigators hypothesis is higher table height will improve the laryngeal exposure.

eight anesthesiologists will be participated. for each anesthesiologist, 20 patients will be enrolled and they will be randomly allocated into one of 4 groups; t10, t8, t6 or t4. the height of operating table will be adjusted prior to commencement of anesthesia induction to place the patient's forehead at one of four anesthesiologist's dermatome levels (t10, t8, t6 or t4) depending on the group. the best laryngeal views will be graded before and after the anesthesiologist's postural change to improve laryngeal visualization of the patient during intubation. subjective and objective measurement of anesthesiologists' joint flexion during intubation and discomfort ratings for the mask ventilation or intubation will be recorded.

Eligibility criteria:
inclusion criteria: * have experiences of more than 100 cases of endotracheal intubation exclusion criteria: * have acute or chronic musculoskeletal disease or pain
clinical characteristics and outcomes in patients diagnosed with novel influenza a (h1n1)

Conditions: Influenza

Summary: this is study where medical record information will be collected as well as collection of excess biological samples.

patients diagnosed with h1n1 will be asked to consent and allow us to collect the following: from the medical record the research staff will review and record the results of the test/procedures (x-rays, ct-scans, ekg (electrocardiogram), etc.) that are part of the subjects clinical care and the results will become part of the research record. we will also collect and record vitals signs, including temperature, blood pressure, heart rate, respiratory rate and record the list of medications the subject is taking. we will also collect information on demographics (address, phone number, etc.) including gender, race and ethnicity, review and record past medical history and any non medical procedures that the subject may have had within the past two months. this information will be collected by the research coordinator from the medical record. the clinical physician ordered a nasopharyngeal swab or obtained bronchoalveolar lavage fluid to diagnose novel influenza a (h1n1). we will collect this swab or fluid after the diagnosis has been made, to evaluate the genetic material of the virus. this swab or fluid is normally discarded once the diagnosis is made. collection of data will be done by the research staff and should not take any longer than 15-20 minutes. the clinical samples that would have been discarded will be collected by the research staff from microbiology and pathology and delivered to the research lab in scaife. the investigators will do a 6 month follow up phone call to check the health status of the participant. this will be done by the research coordinator and take no more than 5-10 minutes of the subject's time.

Eligibility criteria:
inclusion criteria: * patients diagnosed with h1n1 exclusion criteria: * does not meet entry criteria

Keywords: h1n1
combined upper-airway and breathing control therapies for obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the current study combines two treatments for obstructive sleep apnea (osa), oral appliances and supplemental inspired oxygen. the following aims will be tested: aim 1. to determine whether supplemental inspired oxygen further reduces osa severity (apnea-hypopnea index) in patients using an oral appliance. aim 2. to determine whether baseline osa phenotypes can predict the efficacy of oral appliances versus supplemental oxygen versus both treatments in combination. we will test whether responders to oral appliances have distinct pathophysiological characteristics compared with oxygen responders.

pre-specified primary analysis for aim 1 is the change in ahi with combination treatment versus oral appliance alone (%reduction versus placebo; including hypopnea events without desaturation/arousals). aim 2 seeks to identify subgroups of patients that have the greatest reduction in ahi (responders) with each treatment (post-hoc). we will use baseline physiological measures of the four traits causing osa (collapsibility, responsiveness, loop gain, arousal threshold) to determine which characteristics predict responses to each intervention (leave-one-out support vector machine modeling). clinical measures of the same traits will be estimated from the placebo night to confirm that responses can be predicted with clinically-available data. we will also test whether responders to oral appliances have a greater response to oxygen than oral appliance non-responders (and vice-versa), to address whether responders to both treatments are similar or different.

Eligibility criteria:
inclusion criteria: * diagnosed osa or suspected osa based on snoring exclusion criteria: * severe co-morbidities (cardiovascular, renal, lung disease, neurological), including: congestive heart failure, neurological conditions that may affect sleep or breathing (e.g. neuromuscular diseases e.g. myasthenia gravis; neurodegenerative diseases e.g. alzheimer's/parkinson's) * medications that will substantially affect respiration, including opioids, barbiturates, theophylline, doxapram, acetazolamide, pseudoephedrine * claustrophobia * insomnia and other non-respiratory sleep disorders * inability to sleep supine * contraindications to oral appliances, including insufficient teeth to support the device, periodontal problems inducing tooth mobility, active temporomandibular joint disorder * allergy to lidocaine or oxymetazoline hcl

Keywords: obstructive sleep apnea ventilatory control instability complex sleep apnea
a study to evaluate the safety, tolerability and efficacy of rz-001 with valganciclovir (vgcv) in subjects with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this is first in human study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of rz-001 when given to subjects with human telomerase reverse transcriptase (htert)-positive hcc.

the study will be conducted in 2 parts. part 1 is a dose escalation study which aims to explore the maximum tolerated dose (mtd) and recommended phase 2 dose (rp2d) after the single escalating dose of the intratumoral (it) injection given through 4 different cohorts. part 2 will consist of dose expansion, exploring clinical activity for the optimal fixed dose based on the results of part 1.

Eligibility criteria:
inclusion criteria: * adult males and females * hepatocellular carcinoma diagnosis (bclc stage b or c) * htert positive expression confirmed during the screening period * ecog score of 0 or 1 * child-pugh score of a to b7 * life expectancy \>= 3 months exclusion criteria: * moderate or severe ascites * history of hepatic encephalopathy * carcinomas other than hcc * current or history of hiv positive * not suitable for inclusion judged by the investigator